Literature DB >> 31591598

Surrogate gene therapy for muscular dystrophy.

Kay E Davies1, Jeffrey S Chamberlain2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31591598     DOI： 10.1038/s41591-019-0604-2

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.

Authors:  Simon Guiraud; Benjamin Edwards; Arran Babbs; Sarah E Squire; Adam Berg; Lee Moir; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150
  1 in total
  6 in total

Review 1.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

Review 2.  Muscular dystrophy: Experimental animal models and therapeutic approaches (Review).

Authors:  Gisela Gaina; Alexandra Popa Gruianu
Journal:  Exp Ther Med       Date:  2021-04-14       Impact factor: 2.447

Review 3.  Muscle spindle function in healthy and diseased muscle.

Authors:  Stephan Kröger; Bridgette Watkins
Journal:  Skelet Muscle       Date:  2021-01-07       Impact factor: 4.912

Review 4.  Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.

Authors:  Sibylle Jablonka; Luisa Hennlein; Michael Sendtner
Journal:  Neurol Res Pract       Date:  2022-01-04

Review 5.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.

Authors:  Thilo M Buck; Jan Wijnholds
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

Review 6.  Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy.

Authors:  Vratko Himič; Kay E Davies
Journal:  Eur J Hum Genet       Date:  2021-02-09       Impact factor: 4.246
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.